Prescient Therapeutics LimitedASX: PTX

June 2019 Appendix 4C - Quarterly

· Issued by Prescient Therapeutics Limited

Filed with ASX · · 9 pages · English

MELBOURNE Australia, 24 July 2019: Clinical-stage targeted oncology company Prescient Therapeutics Limited (ASX: PTX) (“Prescient”) today reported its June 2019 quarter results and operating highlights. Financial update The business ended the quarter with cash reserves of A$9.64 million. This included proceeds from the second tranche of our placement and non-renounceable rights issue which closed

Prescient Therapeutics Limited on 6ix

Story so far

Earlier from Prescient Therapeutics

Later from Prescient Therapeutics

All Prescient Therapeutics news releases